Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Insys Therapeutics (INSY) Share Price

Media coverage about Insys Therapeutics (NASDAQ:INSY) has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insys Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 47.3385711394931 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s rankings:

Insys Therapeutics (NASDAQ:INSY) opened at $10.70 on Friday. The company has a market cap of $784.49, a price-to-earnings ratio of -4.20 and a beta of 0.76. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.

Several research firms have issued reports on INSY. Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research note on Sunday, November 12th. ValuEngine upgraded shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 target price on the stock in a research note on Wednesday, October 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $14.00 target price on shares of Insys Therapeutics in a research note on Wednesday, October 11th. Finally, Jefferies Group lowered their target price on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Insys Therapeutics has an average rating of “Hold” and an average target price of $9.38.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit